Intercellular Lipid Mediators and GPCR Drug Discovery

Dong-Soon Im*

Molecular Inflammation Research Center for Aging Intervention (MRCA) and College of Pharmacy, Pusan National University, Busan 609-735, Republic of Korea

Abstract

G-protein-coupled receptors (GPCR) are the largest superfamily of receptors responsible for signaling between cells and tissues, and because they play important physiological roles in homeostasis, they are major drug targets. New technologies have been developed for the identification of new ligands, new GPCR functions, and for drug discovery purposes. In particular, intercellular lipid mediators, such as, lysosphosphatic acid and sphingosine 1-phosphate have attracted much attention for drug discovery and this has resulted in the development of fingolimod (FTY-720) and AM095. The discovery of new intercellular lipid mediators and their GPCRs are discussed from the perspective of drug development. Lipid GPCRs for lysosphospholipids, including lysosphosphatidylserine, lysosphosphatidylinositol, lysosphosphatidylcholine, free fatty acids, fatty acid derivatives, and other lipid mediators are reviewed.

Key Words: Lipid mediator, GPCR, Lipid, Lysosphospholipid, Fatty acid, Drug discovery

INTRODUCTION TO GPCRS AND NEW TECHNOLOGY

G-protein-coupled receptors

In humans and other multicellular organisms, communication systems connect cells and tissues. Endocrine, immune, and neuronal systems are representative communication methods (Im, 2002). Chemical messages, such as, hormones, autacoids, and neurotransmitters are released from cells and regulate target cells, which have receptors for first messengers. G-protein-coupled receptors (GPCR) are the largest superfamily of receptors for signaling molecules (ligands). Ligands may be amino acids, amine derivatives, peptides, proteins, lipid molecules, and even entities as small as Ca$^{2+}$, the proton, and the photon (Im, 2002).

GPCRs have seven transmembrane $\alpha$-helix domains (Im, 2002), and thus, are sometimes called seven transmembrane receptors (7TM receptors), because G-protein independent signaling have been found for GPCR-activated intracellular signaling (Rajagopal et al., 2010; Shukla et al., 2011). The binding and recognition of first messengers or ligands by GPCRs result in receptor conformational changes (Im, 2002), which lead to G protein activation and the subsequent modulation of effector molecules, such as, adenyl cyclase, phospholipase C and D, and ion channels (Fig. 1) (Im, 2002). Accordingly, the levels of second messengers of cAMP, IP$_3$, and Ca$^{2+}$ are increased and/or decreased. Protein phosphorylation and dephosphorylation by kinases and phosphatases represent down-stream signaling cascades of second messengers. Furthermore, the phosphorylations of GPCRs by GRKs leads to the recruitment of $\beta$-arrestins, which results in desensitization, internalization (recycling), and G-protein-independent signaling (Rajagopal et al., 2010; Shukla et al., 2011). Representative signalings of GPCRs for lysosphosphatic acid (LPA) and sphingosine 1-phosphate (SIP) are illustrated in Fig. 1, although each GPCR may initiate unique signals in different cell types.

The identification of mammalian GPCR sequence $\beta2$-adenergic receptor in 1986 opened a new era in pharmacology, the ‘receptor-hunting period’ (Dixon et al., 1986; Im, 2002). In 2012, Robert J. Lefkowitz and Brian Kobilka received the Nobel Prize in chemistry by their contribution to “studies of GPCRs”. Many receptor molecules for lipid mediators like platelet-activating factor, prostaglandins, leukotrienes, and cannabinoids, have been cloned and identified as GPCRs at the DNA level (Im, 2004). Sequencing of the human genome resulted in the identification of 865 human GPCR genes (Fredriksson et al., 2003), and 367 GPCRs, excluding olfactory receptors, are considered functional receptors (Vassilatis et al., 2003). Based on data supplied by the International Union of Basic and Clinical Pharmacology Committee on recep-
tor nomenclature and drug classification (NC-IUPHAR). 354 GPCRs are now recognized as non-chemosensory GPCRs (Sharman et al., 2011; Davenport et al., 2013). Of these 92 are still classified as ‘orphan receptors’, because their natural ligands have not been identified (Sharman et al., 2011; Davenport et al., 2013). GPCRs for intercellular lipid mediators have been identified and their numbers continue to increase along with the discoveries of new lipid mediators (Im, 2004, 2009).

**New technologies for GPCR drug discovery**

Because GPCRs play important physiological roles in homeostasis, they are major drug targets for drug discovery. About 40% of drugs on the market act on GPCRs as agonists or antagonists (Howard et al., 2001). Drug discovery based on GPCRs is an attractive project for pharmaceutical companies and academic scientists alike. However, technical problems must be overcome (Im, 2002). The traditional techniques of radioligand binding and GTPγS binding have been used along with measurement of second messengers like cAMP, IP3, and Ca2+ and the protein phosphorylation of MAPKs (Yoshida et al., 2012; Zhang and Xie, 2012). When a ligand structure is known, radioligand binding is the best way to measuring affinities with candidate compounds, but information on whether a test compound is agonist or antagonist is not available and the radiomaterials are strictly regulated, which militate against this analysis method (Yin et al., 2009; Zhang and Xie, 2012; Southern et al., 2013).

A major obstacle to GPCR drug discovery is that each GPCR utilizes different sets of G proteins, such as, Gs, Gi, Gq, or Gz. Therefore, to analyze, promiscuous Gz16, or chimeric G proteins like Goq were popularly adapted for GPCR drug discovery, like Ca2+ measurements by FLIPR (Molecular Devices), by many companies (Kostenis, 2004). Another way of overcoming this hurdle is to screen for β-arrestin recruitment, which is a later response of GPCR than Ca2+ response (Southern et al., 2013). Many other high-throughput screening methods have been devised for GPCR activation analysis, such as, the use of frog melanophores as host cells (Lemer, 1994) or of artificial cell lines transfected with promoter/reporter genes, such as, luciferase or β-lactamase (Bresnick et al., 2003). Because recent excellent review articles are available (Yoshida et al., 2012; Zhang and Xie, 2012), a new technology named TGF-α shedding would be briefly introduced, which was applied for GPCR identification for a lipid mediator, lysophosphatidylserine (LPS) (Inoue et al., 2012).

TGF-α shedding is a new technique for GPCR ligand screening, signaling, agonism and antagonism (Inoue et al., 2012). It uses an engineered plasmid encoding alkaline phosphatase and a TGF-α domain (AP-TGF-α). For example, HEK293 cells, which express endogenous TACE (also known as ADAM-17), are transfected with a candidate or testing GPCR along with the engineered AP-TGF-α. When GPCR is activated, TACE will cut off AP domain from AP-TGF-α, and thus, measures of alkaline phosphatase activities in media (AP release) and in cells (remaining AP-TGF-α) gives infor-

---

**Fig. 1.** Schematic diagram of lipid-mediated signal transduction pathways. For cellular responses, LPA activates LPA2, which leads to activation of phospholipase C (PLC). Activated PLC produces IP3 and diacylglycerol (DAG), DAG activates protein kinase C (PKC), and IP3 mobilizes Ca2+ from internal Ca2+ stores by activating IP3 receptors. The resulting increase in intracellular Ca2+ activates calmodulin-dependent protein kinases. Alternatively, S1P activates S1P1, which leads to inhibition of adenylyl cyclase and the activations of ras, MAPK, PI3K, and AKT via Gi proteins. For desensitization, S1P activates S1P1, which leads to GRK2 activation, S1P1 phosphorylation, and to the recruitment β-arrestins by S1P1. The recruited β-arrestins then inhibit S1P1-G protein coupling.
mation on whether the activation state and degree of activation of GPCR (Inoue et al., 2012). Of the 116 GPCRs tested, 104 were detected by the TGF-α-shedding assay, the highest percentage in a single assay format achieved for GPCR (Inoue et al., 2012).

**INTERCELLULAR LIPID MEDIATORS AND GPCRS**

**Intercellular Lipid Mediators**

Intercellular lipid mediators are defined as chemical transmitters possessing water-insoluble moieties (Im, 2004). Intercellular lipid mediators are hormone-like signaling molecules, but they have the structural and physicochemical characteristics of lipids, such as, first messengers of prostaglandins and leukotrienes (Im, 2004). These mediators can be divided into two groups: one with receptors in the plasma membrane and the other with intracellular nuclear receptors, such as, corticosteroids (Im, 2004). Many intracellular lipid mediators act on GPCRs in the plasma membrane, such as, cannabinoids, platelet-activating factor, prostaglandins, leukotrienes, and lyosphospholipids (Im, 2004; Choi and Chun, 2013).

Certain lipid mediators have two types of receptors, that is, GPCR and nuclear receptors (Im, 2004). Estrogen and bile acids are representative examples, because they act not only through their nuclear receptors (estrogen receptor (ER) and farnesoid X receptor (FXR)) but also through GPCRs, GPR30 (now renamed GPER) for estrogen and TGR5 (now renamed GPBA) for bile acids (Prossnitz and Barton, 2009). Recently, GPR30 was found to be localized in endoplasmic reticulum (Arterburn et al., 2009) and porcine GPR3 was observed in perinuclear membrane at the germinal vesicle stage of oocytes (Yang et al., 2012). On the other hand, constitutive active rat GPR6 was shown to be localized in intracellular compartments (Padmanabhan et al., 2009). Additionally, there is a growing evidence that GPCRs function in nuclear membranes (Zhu et al., 2006; Goetzl, 2007). Therefore, it is incorrect to say that GPCRs act only in the plasma membrane. GPCR signaling in intracellular organelles, such as, endosomes and the nucleus, remains an interesting topic for future research (Irannejad et al., 2013).

**GPCRs for LPA and S1P**

Since the first LPA receptor was identified in 1997, three Edg-subfamily members of LPA receptors and three purinergic (non-Edg) LPA receptors have been reported (Choi and Chun, 2013; Yanagida et al., 2013). GPR23 and two additional purinergic GPCRs, that is, GPR92 and P2Y5, were confirmed as LPA receptors and renamed LPA1, LPAα, and LPAβ, respectively (Chun et al., 2010; Yanagida et al., 2013). Although GPR92/LPA1 was reported to be a receptor for farnesyl pyrophosphate and N-arachidonylglycine (Oh et al., 2008), their affinity was found to be lower than LPA in a β-arrestin assay and in a aequorin assay (Yin et al., 2009). Peroxisome proliferation-activating receptor (PPARγ) has been reported to be a non-GPCR LPA receptor (McIntyre et al., 2003), but further validation is required (Chun et al., 2010). LPAα, antagonist AM095, which is a lead compound for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma, is currently undergoing under clinical trials (Castelino et al., 2011; Swaney et al., 2011).

In addition, to the six LPA receptors, three orphan GPCRs have been proposed to be LPA receptors. GPR87 was reported to be an LPA receptor (Tabata et al., 2007). P2Y10 has been reported to be a GPCR for S1P and LPA (Murakami et al., 2008). P2Y10 was recently proposed to be an LPS receptor (Inoue et al., 2012). GPR35 was also suggested to be an LPA receptor, especially for 2-arachidonyl LPA (Oka et al., 2010). However, a consensus was reached in the scientific community to exclude these putative LPA receptors from the current list of LPA receptors, pending future experimental validation (Chun et al., 2010).

Five members of the Edg-subfamily GPCRs (S1P1–5) have also been reported to be S1P receptors (Chun et al., 2010). Drug research on S1P receptor has been boosted by the finding of the S1P modulation of lymphocyte egress by FTY720 (Oyster and Schwab, 2012). FTY720 is an immune modulator and is phosphorylated in vivo. In the phosphorylated state, FTY720 acts as an agonist on four S1P receptors and as a functional antagonist on S1P1, (Im, 2003). FTY720 (fingolimod, Gilenya® Novartis) was approved as a first-line oral treatment for relapsing-remitting multiple sclerosis by the US FDA (Obinata and Hla, 2012). Recently, a potent and selective S1P1 antagonist, NIBR-0213, was shown to suppress autoimmune inflammation in an experimental autoimmune encephalomyelitis model in mice (Quancard et al., 2012).

GPR3, GPR6, and GPR12 have been reported to be GPCRs for S1P and SPC. S1P was reported as a ligand for GPR3 and GPR6 and SPC for GPR12 (Im, 2004). These three GPCRs are phylogenetically similar to other GPCRs for lipid mediators, such as, LPA, S1P, and cannabinoids (Fig. 2) (Im, 2004), and were initially reported as adenylyl cyclase-activating orphan GPCRs (Eggerickx et al., 1995). The constitutive activation of adenylyl cyclase by GPCR was continuously observed in GPR3-, GPR6-, and GPR12-expressing cells, not only in over-expressing cells in vitro but also in cells in vivo.

**Fig. 2.** Phylogenetic tree of lipid GPCRs. The phylogenetic tree was constructed using the Clustal Omega multiple sequence alignment and TreeIllustrator programs.
Furthermore, some reports support the activation of GPR3 by S1P. More specifically, the constitutive activation of adenylyl cyclase by GPR3 and the further activation of adenylyl cyclase by S1P, resulted in the accumulation of cAMP (Hinckley et al., 2005; Zhang et al., 2012). In addition, S1P was observed to induce the internalization of GFP-tagged porcine GPR3 (Zhang et al., 2012), whereas SPC did not (Yang et al., 2008b; Padmanabhan et al., 2009; Zhang et al., 2012).

| Table 1. Summary of recent GPCRs for intercellular lipid mediators |
|---------------------------------------------------------------|
| GPCR  | Suggested Ligand | IUPHAR name | Remark | Ref |
|-------|------------------|-------------|--------|-----|
| EDG2, EDG4, EDG7 | LPA | LPA\(_1\), LPA\(_2\), LPA\(_3\) | Chun et al., 2010 |
| GPR23, GPR92, P2Y5 | LPA | LPA\(_4\), LPA\(_5\), LPA\(_6\) | Chun et al., 2010 |
| EDG1, EDG5, EDG3, EDG6, EDG8 | S1P | S1P\(_1\), S1P\(_2\), S1P\(_3\), S1P\(_4\), S1P\(_5\) | Chun et al., 2010 |
| GPR3, GPR6, GPR12 | S1P, SPC (?) | Constitutive activity | Ignatov et al., 2003; Uhlenbrock et al., 2002 |
| GPR87 | LPA (?) | Tabata et al., 2007 |
| GPR35 | LPA | 2-arachidonoyl LPA | Oka et al., 2010 |
| GPR55 | LPI | 2-arachidonoyl LPI | Oka et al., 2009 |
| P2Y10 | S1P, LPA (?) LPS (?) | Murakami et al., 2008; Inoue et al., 2012 |
| GPR34 | LPS | 2-acyl LPS | Kitamura et al., 2012; Sugo et al., 2006 |
| GPR174 | LPS (?) | Inoue et al., 2012 |
| GPR40, GPR43, GPR41, GPR120 | Free fatty acids | FFA\(_1\), FFA\(_2\), FFA\(_3\), FFA\(_4\) | Davenport et al., 2013 |
| GPR84 | Free fatty acids | Hydroxy fatty acids | Suzuki et al., 2013; Wang et al., 2006b |
| GPR119 | OEA, LPC | Fatty acid derivatives | Ovortn et al., 2006; Soga et al., 2005 |
| G2A | LPS, LPC, H\(_2\), 9-HODE | Fatty acid derivatives (?) | Frasch et al., 2013; Obinata et al., 2005; Parks et al., 2005 |
| GPR30 | Estrogen | GPER | Prossnitz and Barton, 2009 |
| TGR5/BG37 | Bile acid | GPBA | Kawamata et al., 2003 |
| TG1019 | 5-ox-ETE | OXE | oxo ETE | Grant et al., 2009 |
| GPR31 | 12-S-HETE | Hydroxy ETE | Guo et al., 2011 |
| BAI1 | PS | | Park et al., 2007 |
| GPR17 | CysLT (?) nucleotides (?) | Constitutive activity CysLTD\(_4\), UDP-glucose | Ciana et al., 2006; Maekawa et al., 2009; Qi et al., 2013 |
| GPR18 | NAG (?) | Constitutive activity | Kohno et al., 2006 |
| GPR183 | Oxysterols | 7\(_\alpha\),25-dihydrocholesterol | Hannedouche et al., 2011; Liu et al., 2011 |

S1P: sphingosine 1-phosphate; SPC: sphingosylphosphorylcholine; LPA: lysophosphatidic acid; FFA: free fatty acid; OEA: oleylethanolamide; 5-oxo-ETE: 5-oxo-ETE, 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid; LPC: lysophosphatidylcholine; LPI: lysophosphatidylinositol; LPS: lysophosphatidylserine; PS: phosphatidylserine; NAG: N-arachidonylglycine; 9-HODE: 9-hydroxyoctadecenoic acid; 12-S-HEPE: 12-(S)-hydroxyeicosatetraenoic acid.
et al., 2012), and in the same study, SPC significantly delayed germinal vesicle breakdown in porcine oocytes. On the other hand, other did not observe any additional effect of S1P on the accumulation of cAMP, despite reproducing the increased production of cAMP in GPR3-expressing cells (Valverde et al., 2009). Furthermore, S1P was not found to be a GPCR ligand in a β-arrestin PathHunter™ assay (Yin et al., 2009; Southern et al., 2013). Therefore, NC-IUPHAR is currently classified them as constitutively active orphan GPCR (Davenport et al., 2013).

Nevertheless, there is growing evidence that GPR3 participates in the regulations of oocyte maturation and neurologic states. The constitutive activation of Gs proteins by GPR3 and its role in the prophase I meiotic arrest of oocytes have been shown in Xenopus, rodent, and in human oocytes and even in GPR3-knock-out mice (Freudtson et al., 2005; Hinkley et al., 2005; DiLuigi et al., 2008a). Additionally, GPR3 has been proposed to participate in neurite outgrowth (Tanaka et al., 2007), postnatal cerebellar development (Tanaka et al., 2009), emotional-like responses (Valverde et al., 2009), Alzheimer’s disease (Thathiah et al., 2009), the early phases of cocaine reinforcement (Tourino et al., 2012), and neuropathic pain therapy (Ruiz-Medina et al., 2011).

GPR63 was initially reported as a GPCR recognizing S1P and dioleoyl phosphatidic acid (Niedermberg et al., 2003), but not much progress has been made on this pairing. Like the suggestion based on phylogenetic bioinformatic analysis of GPCRs, lipid ligands might not be correct for GPR63, because sequentially related neighbor GPCRs form a large class of peptide receptors (Vassilatis et al., 2003; Im, 2004).

**GPCRs for LPC and LPS**

GPR1 (GPR68), GPR4, TDAG8 (GPR65), and G2A (GPR132), which compose a subfamily of GPCRs, were initially reported to be lipid receptors for spinosyns/phyosphorylcholine (SPC), lysophosphatidylcholine (LPC), and psychosine (Im, 2005; Tomura et al., 2005). Later, all four members were found to be proton-sensing GPCRs (Tomura et al., 2005), and original reports on GOR1, GPR4, and G2A were later retracted. Although NC-IUPHAR has classified all four as orphan GPCRs (Davenport et al., 2013), GOR1, GPR4, and TDAG8 continue to be reported as proton-sensing GPCRs in terms of the physiological and pathological relevances even in knockout mice (Okajima, 2013). On the other hand, G2A, a weak proton-sensing GPCR (Radu et al., 2005), has been studied in various contexts.

Firstly, 9-hydroxyoctadecenoic acid (9-HODE) was reported to be a ligand for human G2A/GPR132, but not for mouse G2A (Obinata et al., 2005; Obinata and Izumi, 2009) and this was confirmed using the β-arrestin PathHunter™ assay (Yin et al., 2009). Additionally, oxidized free fatty acids, such as, 9(S)-HODE, 9-hydroperoxyoctadecenedioic acid, and 11-HEPE, have been reported to be potent agonists of G2A, but LPC, 13(S)-HODE, and lauric acid were found to leave G2A unaffected in the β-arrestin assay (Yin et al., 2009). Secondly, the regulatory functions of G2A have been studied in atherosclerosis, autoimmunity, and gallstone formation in G2A knockout mice (Johnson et al., 2008; Kabarowski, 2009). Thirdly, Brantton’s group suggested interesting roles for LPS in resolution of inflammation (Frasch and Bratton, 2012; Frasch et al., 2013). LPS is made in activated neutrophils and LPS in the plasma membrane of neutrophils regulates macrophage effectorcytosis and phenotype changes to M2 in a G2A-dependent manner in macrophages, and this finding was supported using G2A knockout mice (Frasch et al., 2013). Previously, this group reported that LPC, LPS, and LPE mobilize neutrophil secretory vesicles and induce redundant signaling through G2A (Frasch et al., 2007). A similar LPC-induced surface redistribution of G2A was shown in a previous study (Wang et al., 2005). However, G2A involvement in lysophospholipid-induced Ca2+ signaling has been demonstrated only with antibody to G2A, such as, in experimental sepsis (Yan et al., 2004; Frasch et al., 2007).

GPR119 is largely restricted to pancreatic insulin-producing β cells and intestinal glucagon-like peptide-1-producing L-cells, and was first reported as a receptor for oleoyl-LPC, which enhances glucose-induced insulin secretion (Soga et al., 2005). The ranking order lysophospholipid was found to be 18:1-LPC, 16:0-LPC>18:0-LPC>LPE, and LPC in RH7777 rat hepatoma cells stably expressing human GPR119 (Soga et al., 2005). Later, N-oleoylthanolamide (OEA) was shown to activate GPR119 more potently than LPC (Overton et al., 2006). N-Oleoylphosphatidylethanolamine was also reported as an agonist of GPR119 (Chu et al., 2010), and 2-oleoylglycerol was proposed as an endogenous agonist in food for GPR119 (Hansen et al., 2011). Therefore, the stimulatory effect of dietary fat on incretin secretion (GLP-1 from L cells) and insulin secretion (β cells) may be mediated through GPR119 via multiple derivatives of oleate (C18:1) (Davenport et al., 2013). Furthermore, the hypoglycic effect (reduction of food intake) of GPR119 has made it a focus of anti-diabetic drug development (Overton et al., 2008). In fact, over a hundred papers have described the development of potent GPR119 agonist and preclinical and clinical data suggest that GPR119 agonists will be the next generation of compounds used to treat type 2 diabetes mellitus (Shah and Kowalski, 2010; Davenport et al., 2013).

LPS is an activator of mast cell degranulation, and has been reported to be a ligand for GPR34, which is highly expressed in mast cells (Sugo et al., 2006); however, this pairing is somewhat controversial (Iwashita et al., 2009; Liebscher et al., 2011; Ritscher et al., 2012). Kitamura et al. showed using several methods that GPR34 is a receptor of LPS with a fatty acid at the sn-2 position (Kitamura et al., 2012). Recently, additional members of GPCRs, such as, GPR174 and P2Y10, were putatively suggested using a TGF-α shedding assay (Inoue et al., 2012).

**GPCRs for LPI**

In addition to the classical cannabinoid receptors CB1 and CB2, cannabinoid GPCRs, have been implicated in studies on CB1 and CB2 knock-out mice and in studies using cannabinoid mimetic chemicals. Although phylogenetically distant from CB1 and CB2 receptors, several groups have reported that GPR55 is a cannabinoid receptor (Baker et al., 2006; Johns et al., 2007; Ryberg et al., 2007). However, Sugiuara et al. were unable to reproduce this result and instead suggested lysophosphatidylinositol (LPI, 2-arachidonyl-sn-glycero-3-phosphoinositol) as a ligand (Oka et al., 2007, 2009), whereas other groups suggested that GPR55 is atypical as a cannabinoid receptor and in terms of its signaling (Johns et al., 2007; Lauckner et al., 2008). In 2010, NC-IUPHAR decided not to include GPR55 as a cannabinoid receptor (Pertwee et al., 2010). However, the consensus is that LPI acts as an endogenous agonist on GPR55 (Pineiro and Falasca, 2012).
In this context, Yamashita et al. proposed that phylogenetically neighboring GPR55 and GPR35 evolved to share ligand recognition properties, that is, GPR35 recognizes 2-arachidonyl LPA and GPR55 recognizes 2-arachidonyl LPI (Yamashita et al., 2013). GPR35 was initially reported to be a receptor for kynurenic acid, a metabolite of tryptophan (Wang et al., 2006a). Although kynurenic acid is able to activate GPR35, it has considerably lower potency for human GPR35 than rat GPR35 (Jenkins et al., 2011). Many surrogate ligands for GPR35, such as, zaprinast, cromolyn sodium, loop diuretics, and pamoic acid have been identified (Zhao and Abood, 2013). The importance of GPR35 in pain (spinal antinociception and inflammatory pain), heart disease, asthma, inflammatory bowel disease, and cancer has compelled scientists to find novel agonists and antagonists (Neetoo-Isseljee et al., 2013).

**GPCRS FOR FREE FATTY ACIDS**

GPR40, GPR43, GPR41, and GPR120 act as receptors for short chain (GPR41 and GPR43), medium long chain (GPR40), and unsaturated long chain fatty acids (GPR120) (Telukdar et al., 2011; Hara et al., 2013). IUPHAR renamed them FFA$_1$, (GPR40), FFA$_2$ (GPR43), FFA$_3$ (GPR41), and FFA$_4$ (GPR120) (Davenport et al., 2013). GPR84 has also been reported to act as a receptor for medium chain fatty acids of carbon chain lengths C9 to C14 (Wang et al., 2009). However, it has not been nominated yet to be FFA$_5$ (Davenport et al., 2013). Interestingly, GPR84-deficient mice showed regulation of early IL-4 gene expression in activated T cells (Venkataraman and Kuo, 2005). In a recent study, it was suggested that medium chain fatty acids with a hydroxyl group at the 2- or 3-position are more efficacious than non-hydroxylated fatty acids, and identified 6-octylaminouracil as a surrogate agonist (Suzuki et al., 2013). Southern et al. confirmed that the medium chain fatty acids capric acid, undecanoic acid, and eicosatetraenoic acid evoke GPR84-mediated β-arrestin recruitment, cAMP, and calcium signaling (Southern et al., 2013). Therefore, it may only be a matter of time before it is renamed FFA$_5$. The regulations of glucagon-like peptide-1 secretion from intestinal L cells and insulin from pancreatic β cells by free fatty acids via GPR120 and GPR40 are crucial considerations of the development of future treatments for diabetes. Because many review articles have been published on the topic of free fatty acids and their GPCRs, the reader is recommended to read (Telukdar et al., 2011; Hara et al., 2013).

**CONSTITUTIVELY ACTIVE GPCRS, GPR17, GPR18, AND GPR183**

GPR17 was initially reported to be a new dual uracil nucleotide/cysteinyl-leukotrienes receptor (Ciana et al., 2006). Later, Maekawa et al. suggested that GPR17 is a ligand-independent, constitutive negative regulator of CysLT, that suppresses CysLT$_1$-mediated function at the cell membrane (Maekawa et al., 2009). Qi et al. recently confirmed this observation, that is, by lack of activation by UDP-glucose or CysLTs (Qi et al., 2013).

Another group reported the differential expressions of two isoforms of GPR17 in human brain (short) and heart and lung (long). Furthermore, although activation of GPR17 by uracil nucleotides (UDP, UDP-glucose, and UDP-galactose) was observed, but not by cysteinyl-leukotrienes (LTD$_4$) (Benned-Jensen and Rosenkilde, 2010). Thus, the cognate ligands of GPR17 remain controversial (Davenport et al., 2013). Because GPR17 has been reported to be a regulator of many physiological and pathological processes, including brain injury, spinal cord injury, oligodendrocyte differentiation, and food intake (Ren et al., 2012; Coppi et al., 2013; Franke et al., 2013), it offers a good therapeutic target, especially for neurorepair after traumatic brain injury (Franke et al., 2013). Both short and long forms of GPR17 have been reported to be constitutively activated via Gi protein activation (Benned-Jensen and Rosenkilde, 2010), and this constitutive activity could have functional meaning, as it does for GPR3.

GPR18, an orphan GPCR in lymphoid cell lines, such as, those of the spleen and thymus, was suggested to be a receptor for N-arachidonylglycerine (NAG) (Kohn et al., 2006). NAG is an endogenous metabolite of endocannabinoid anandamide (N-arachidonyl ethanolamine), and McHugh et al. found NAG and abnormal cannabidiol induced the cellular migration of BV-2 microglia, endogenously GPR18 expressing microglia, and exogenously GPR18-transfected HEK293 cells (McHugh et al., 2010). Furthermore, GPR18 was found to be the most abundantly overexpressed orphan GPCR in 40 metastatic melanomas (Qin et al., 2011). McHugh et al. reported that anandamide, ∆THC, or NAG induced the migration of human endometrial HEC-1B cells, which express GPR18 (McHugh et al., 2012). However, the pairing of GPR18 with NAG was not reproduced in a β-arrestin PathHunter$^{®}$ assay (Yin et al., 2009; Southern et al., 2013) or in GPR18-expressing neurons (Lu et al., 2013), and GPR18 was found to be constitutively active to inhibit the apoptosis (Qin et al., 2011).

EBI2 (also known as GPR183) was initially identified as one of nine up-regulated genes in Epstein-Barr virus (EBV)-infected Burkitt lymphoma cells and to show constitutive activity via Gi protein (Rosenkilde et al., 2006). Oxysters (oxygenated cholesterol derivatives) have been shown to activate EBI2, and 7α,25-dihydroxycholesterol was the most potent (Hamedouche et al., 2011; Liu et al., 2011), which thereby, unexpectedly linked EBI2 (an orphan GPCR that controls B-cell migration) and the immunological effects of certain oxyesters, and also suggested that the EBI2-oxysterol signaling pathway play an important role in the innate and adaptive immune systems (Spann and Glass, 2013).

**GPCRS FOR OTHER LIPID MEDIATORS**

Brain-specific angiogenesis inhibitor-1 (BAI1), an adhesion-type GPCR with an extended extracellular region, has been reported to be a phosphatidylserine (PS) recognition receptor (Park et al., 2007). PS is known as a key ‘eat-me’ signal exposed on the outer leaflet of apoptotic cells, and BAI1 has been reported to function as an engulfment receptor for both the recognition and subsequent internalization of apoptotic cells (Park et al., 2007; Bratton and Henson, 2008). The roles of BAI1 in the non-opsonic phagocytosis of Gram-negative bacteria, the fusion of healthy myoblasts, synaptogenesis, and the inhibition of tumor growth and angiogenesis via proteolytically processed extracellular domains, such as, vascostatin (Vstat120), have been investigated (Kaur et al., 2013).
Bile acids are being increasingly appreciated as complex metabolic integrators and signaling factors (Thomas et al., 2008), although they have long been known to be essential in dietary lipid absorption and cholesterol catabolism (Watanabe et al., 2006). TGR5 (now renamed GPBA) is a receptor for bile acids (Maruyama et al., 2002; Kawamata et al., 2003), and thus, bile acid signal not only through nuclear hormone receptors, such as, farnesoid X receptor α (FXR-α), but also through GPBA. The administration of bile acids to mice increased energy expenditure in brown adipose tissue, preventing obesity and resistance to insulin due to GPBA activation (Watanabe et al., 2006). The targeted disruption of TGR5 in mice resulted in significant fat accumulation and body weight gain versus wild type mice when both were fed a high fat diet (Maruyama et al., 2006). In another study, high TGR5 expression in gall bladder was observed with a marked reduction in gallstone development in TGR5−/− mice on a lithogenic diet (Vassileva et al., 2006). The main indication for the development of TGR5 agonists is for the treatment of obesity, that is, to exploit the effect of the receptor on the regulating off energy expenditure (Fiorucci et al., 2009).

GPR30 (now renamed as GPER) responds to estrogen with rapid cellular signaling (Prossnitz and Barton, 2009). A GPR30 antagonist, G-15, was discovered by high throughput flow cytometry (HyperCyt®) with fluorescent estrogen ligands (both cell permeable and non-permeable), which also elegantly showed GPR30 expression in endoplasmic reticulum and not in the plasma membrane (Arterburn et al., 2009). GPER-selective ligands and GPR30 knockout mice have allowed the elucidation of GPER functions in many cases, which suggests that estrogen-mediated physiological responses may be mediated by either the receptor or a combination of GPER and nuclear ER receptors (Prossnitz and Barton, 2009). Furthermore, the physiological roles of GPER have expanded from reproductive, endocrine, immune and cardiovascular systems to nervous systems, as exemplified by studies on anxiolysis (Prossnitz and Barton, 2011; Tian et al., 2013).

Serhan et al. discovered resolvin E1, resolvin D1, protectin, and maresin, which are all derivatives of omega-3 fatty acids, such as, DHA and EPA, and found they were anti-inflammatory and pro-resolving lipid mediators like lipoxin A4, a pro-resolving mediator derived from arachidonic acid that plays important roles in the resolution of inflammation (Serhan et al., 2002; Serhan et al., 2008). In addition, resolvin E1 was found to activate GPR1/ChemR23 and to inhibit BLT1. On the other hand, resolvin D1 and lipoxin A4 activated GPR32 and FPR2/ALX for their pro-resolving responses (Serhan et al., 2011). This topic has also been reviewed by experts (Serhan et al., 2011).

OXE, formerly known as TG1019, was reported to recognize eicosatetraenoic acids and polysaturated fatty acids, including 5-oxo-GE, 8Z, 11Z, 14Z-eicosatetraenoic acid (5-oxo-ETE) (Hosoi et al., 2002; Jones et al., 2003; Brink et al., 2004). 5-Oxo-ETE, the most potent agonist of OXE, is the most potent eosinophil chemotactic factor known (Hosoi et al., 2002; Jones et al., 2003). Because 5-oxo-ETE may be an important regulator of tissue infiltration and of the activations of eosinophils and neutrophils in diseases, such as, asthma, allergic rhinitis, arthritis, and psoriasis, OXE selective antagonists are currently under development as therapeutic agents for the treatment of asthma and other allergic diseases (Gore et al., 2013; Powell and Roberto, 2013).

Furthermore, 12-(S)-hydroxyeicosatetraenoic acid (12-S-HETE), a 12-lipoxygenase metabolite of arachidonic acid has been suggested to be a high affinity ligand for GPR31, which is phylogenetically closest to OXE receptor (Guo et al., 2011; Davenport et al., 2013).

PERPORSIVE OF INTERCELLULAR LIPID MEDIATORS AND THEIR GPCRS

Novel lipid mediators and GPCRs have been reviewed a number of times (Kostenis, 2004; Meyer zu Heringdorf and Jacobs, 2007; Grzelczyk and Gendaszewska-Darmach, 2013). In the present review, the statuses of GPCRs as intercellular lipid mediators are reviewed (Table 1). During the last decade, information on some GPCRs, such as, GPR3, GPR6, GPR12, and GPR63, in terms of ligand pairing has not progressed (Davenport et al., 2013). The status of GPR23 (now renamed LPA1) and the statuses of two additional members of purine receptor family, GPR92 (LPA2) and P2Y5 (LPA4) have been confirmed. Furthermore, GPR40, GPR43, and GPR41 are now confirmed GPCRs, and have been renamed free fatty acid receptors 1, 2, and 3 (FFA1, FFA2, and FFA3, respectively) (Davenport et al., 2013). In addition, GPR120 has been renamed fatty acid receptor 4 for long-chain, especially unsaturated fatty acids, like omega-3 DHA and EPA (FFA3) (Davenport et al., 2013). TG1019 has been confirmed as a receptor for 5-oxo-eicosatetraenoic acid (5-oxo-ETE) and renamed OXE receptor (Brink et al., 2003). Drug development targeting TGR5 (GPR131, now renamed GPBA) and GPR30 (now renamed GPER) is being actively pursued for the treatment of lipid and glucose disorders (Davenport et al., 2013). In addition, new GPCRs have been introduced, namely, GPR17, GPR18, GPR31, GPR32, GPR34, GPR35, GPR40, GPR87, GPR119, GPR120, GPR174, GPR183, P2Y10, and BA11 (Davenport et al., 2013).

GPR17, GPR18, and GPR183 have been reported to be constitutively active like GPR3, GPR6, and GPR12 (Eggerickx et al., 1995; Uhambrock et al., 2002; Rosenkilde et al., 2006; Benned-Jensen and Rosenkilde, 2010; Qin et al., 2011), which might be a cause of that ligand-GPCR pairings have been controversial. Care must be taken when ligand-GPCR pairing might be a cause of that ligand-GPCR pairings have been confirmed (Chun et al., 2010; Davenport et al., 2013). In addition, GPCR-GPCR pairing with LPA and S1P could not be supported (Chun et al., 2008). Without confirmation by other assay systems or by other laboratories, the original suggested pairing with LPA and S1P could not be supported (Chun et al., 2010; Davenport et al., 2013). Although BA11 and GPR31 were respectively reported in a single paper, multiple assays...
were carefully undertaken (Park et al., 2007; Guo et al., 2011). The pairings of P2Y10 and GPR114 with LPS were found in TGF-β shedding assay (Inoue et al., 2012). Further studies are required to confirm the pairing results in the future.

Of the newly found lipid GPCRs, drug development targeting GPR119 is undoubtedly the most active field, because it is related to the treatment of diabetes (Shah and Kowalski, 2010; Ohishi and Yoshida, 2012). Fundamental studies on pathophysiologies of other GPCRs should provide bases for future GPCR drug development.

ACKNOWLEDGMENTS

This work was supported by the Korean National Research Foundation funded by the Korean government (MSIP) (Grant no. 2009-008358).

REFERENCES

Baker, D., Pryce, G., Davies, W. L. and Hiley, C. R. (2006) In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 27, 1-4.

Bresnick, J. N., Skynner, H. A., Chapman, K. L., Jack, A. D., Zamiera, E., Negulescu, P., Beaumont, K., Patel, S. and McAllister, G. (2003) Identification of signal transduction pathways used by orphan g protein-coupled receptors. Assay Drug Dev. Technol. 1, 239-249.

Brink, C., Dahlen, S. E., Drazen, J., Evans, J. F., Hay, D. W., Nicosia, S., Serhan, C. N., Shimizu, T. and Yokomizo, T. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. 55, 195-227.

Brink, C., Dahlen, S. E., Drazen, J., Evans, J. F., Hay, D. W., Rovati, G. E., Serhan, C. N., Shimizu, T. and Yokomizo, T. (2004) International Union of Pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor. Pharmacol. Rev. 56, 149-157.

Castelino, F. V., Seders, J., Bain, G., Brooks, S. F., King, C. D., Swaney, J. S., Lorrain, D. S., Chun, J., Luster, A. D. and Tager, A. M. (2003) Amelioration of dermal neurovasculature, and tumor development. J. Mol. Med. (Berl) 89, 743-752.

Cyster, J. G. and Schwab, S. R. (2012) Sphin cage-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30, 69-94.

Davison, A. P., Alexander, S. P., Sharmann, J. L., Pawsow, A. J., Benison, H. E., Monaghan, A. E., Liew, W. C., Mpmamhanga, C. P., Bonfer, T. I., Neubig, R. R., Pin, J. P., Spedding, M. and Harmar, A. J. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol. Rev. 65, 967-986.

DI Luigi, A., Weitzein, V. N., Pace, M. C., Siano, L. J., Maier, D. and Mehmihan, L. M. (2008a) Meiotic arrest in human oocytes is maintained by a Gs signaling pathway. Biol. Reprod. 78, 667-672.

DI Luigi, A. J., Maier, D. B. and Benadiva, C. A. (2008b) Ruptured ectopic pregnancy with contralateral adnexal torsion after spontaneous conception. Fertil. Steril. 90, e1-3.

Dixon, R. A., Kobikla, B. K., Strader, D. J., Benovic, L. J., Dohman, H. G., Friele, T., Bolanowski, M. A., Bennett, C. D., Rands, E., Diehl, R. E. and et al. (1986) Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 321, 75-79.

Duman, J. G., Tseng, C. P., Tu, Y. K., Munjal, T., Schwecther, B., Ho, R. T. S. and Toliais, K. F. (2013) The adhesion-GPCR BAII regulates synaptogenesis by controlling the recruitment of the Par3/Tiam1 polarity complex to synaptic sites. J. Neurosci. 33, 6964-6978.

Eggerickx, D., Dene, J. F., Labbe, O., Hayashi, Y., Refetoff, S., Vassart, G., Parmentier, M. and Libert, F. (1995) Molecular cloning of an orphan G-protein-coupled receptor that activates adenylate cyclase. Biochem. J. 309 (Pt 3), 837-843.

Fiorucci, S., Mencarelli, A., Palladino, G. and Cipriani, S. (2009) Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci. 30, 570-580.

Franke, H., Parravicini, C., Lecca, D., Zanier, E. R., Heine, C., Lundin, L. G. and Schioth, H. B. (2009) Lysophospholipid receptor fingerprints. Prog. Lipid Res. 51, 1256-1272.

Frasch, S. C. and Bratton, D. L. (2012) Emerging roles for lysosphosphatidylserine in resolution of inflammation. Prog. Lipid Res. 51, 199-207.

Frasch, S. C., Fernandez-Boyanapalli, R. F., Berry, K. A., Murphy, R. C., Leslie, C. C., Nick, J. A., Henson, P. M. and Bratton, D. L. (2013) Neutrophils regulate tissue Neutrophilia in inflammation via the oxidant-modified lipid lysosphosphatidylserine. J. Biol. Chem. 288, 4583-4593.

Frasch, S. C., Zemski-Berry, K., Murphy, R. C., Borregaard, N., Henson, P. M. and Bratton, D. L. (2007) Lysosphospholipid s of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A. J. Immunol. 178, 6540-6548.

Fredriksson, R., Lagerstrom, M. C., Lundin, L. G. and Schioth, H. B. (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralgon groups, and fingerprints. Mol. Pharmacol. 63, 1256-1272.

Freudzon, L., Norris, R. P., Hand, A. R., Tanaka, S., Saei, Y., Jones, T. L., Rasenick, M. M., Berlot, C. H., Mehmihan, L. M. and Jaffe, L. A. (2005) Regulation of meliotic prophase arrest in mouse oocytes.
by GPR3, a constitutive activator of the Gs protein. J. Cell Biol. 171, 255-265.

Goetzl, E. J. (2007) Diverse pathways for nuclear signaling by G protein-coupled receptors and their ligands. FASEB J. 21, 638-642.

Gore, V., Patel, P., Chang, C. T., Sivindran, S., Kang, N., Ugedrao, Y. P., Gravel, S., Powell, W. S. and Rokach, J. (2013) 5-Oxo-ETE receptor antagonists. J. Med. Chem. 56, 3725-3732.

Grant, G. E. G., Rokach, J. and Powell, W. S. (2009) 5-Oxo-ETE and the OXRs: A new family of receptor. Prostaglandins Other Lipid Mediat. 89, 98-104.

Grezczyk, A. and Gendaszewska-Darmach, E. (2013) Novel bioactive glycerol-based lysophospholipids: new data – new insight into their function. Biochimie 95, 667-679.

Guo, Y., Zhang, W., Giroux, C., Cai, Y., Ekambaram, P., Dilly, A. K., Hu, Y., Zhao, C. S., Mao, L., Yue, D., Liao, L., Zhang, K., Li, Y., Zhang, X., Zhu, J., Lee, M. J. and Henn, K. V. (2011) Identification of the orphan G protein-coupled receptor GPR3 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid. J. Biol. Chem. 286, 33832-33840.

Hannenedouche, S., Zhang, J., Yi, T., Shen, W., Nguyen, D., Pereira, J. P., Guo, N., Tsuchiya, S., Tsuchiya, T. and Shi, J. (2002) Kainic acid-activated K(v)3.2 potassium channels in the rat retina. J. Neurosci. 22, 538-546.

Hara, T., Kimura, I., Inoue, D., Ichimura, A. and Hirasawa, A. (2013) Novel bioactive glycerol-based lysophospholipids: new data – new insight into their function. Biochimie 95, 667-679.

Guo, Y., Zhang, W., Giroux, C., Cai, Y., Ekambaram, P., Dilly, A. K., Hu, Y., Zhao, C. S., Mao, L., Yue, D., Liao, L., Zhang, K., Li, Y., Zhang, X., Zhu, J., Lee, M. J. and Henn, K. V. (2011) Identification of the orphan G protein-coupled receptor GPR3 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid. J. Biol. Chem. 286, 33832-33840.

Hannenedouche, S., Zhang, J., Yi, T., Shen, W., Nguyen, D., Pereira, J. P., Guo, N., Tsuchiya, S., Tsuchiya, T. and Shi, J. (2002) Kainic acid-activated K(v)3.2 potassium channels in the rat retina. J. Neurosci. 22, 538-546.

Hara, T., Kimura, I., Inoue, D., Ichimura, A. and Hirasawa, A. (2013) Novel bioactive glycerol-based lysophospholipids: new data – new insight into their function. Biochimie 95, 667-679.

Guo, Y., Zhang, W., Giroux, C., Cai, Y., Ekambaram, P., Dilly, A. K., Hu, Y., Zhao, C. S., Mao, L., Yue, D., Liao, L., Zhang, K., Li, Y., Zhang, X., Zhu, J., Lee, M. J. and Henn, K. V. (2011) Identification of the orphan G protein-coupled receptor GPR3 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid. J. Biol. Chem. 286, 33832-33840.
and regulates morphine-induced antinociception. Neuropharmaco-

61, 43-50.

ryberg, E., Larsson, N., Sjogren, S., Hjorth, S., Hermansson, N. O.,

Leonova, J., Elebring, T., Nilsson, K., Dromla, T. and Greasley, P. J. (2007) The orphan receptor GPR55 is a novel cannabinoid recep-

tor. Br. J. Pharmacol. 152, 1092-1101.

Serhan, C. N., Chiang, N. and Van Dyke, T. E. (2008) Resolving in-
flammation: dual anti-inflammatory and pro-resolution lipid media-

ators. Nat. Rev. Immunol. 8, 349-361.

Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R.,

Mikr, G. and Moussignac, R. L. (2002) Resolving: a family of bio-

active products of omega-3 fatty acid transformation circuits initi-

ated by aspirin treatment that counter proinflammation signals. J.

Immunol. 169, 1075-1080.

Serhan, C. N., Krishnamoorthy, S., Recchiuti, A. and Chiang, N. (2011)

Novel anti-inflammatory–pro-resolving mediators and their recep-

tors. Curr. Top. Med. Chem. 11, 629-647.

Shah, U. and Kowalski, J. T. (2010) GPR119 agonists for the potential treat-

ment of type 2 diabetes and related metabolic disorders. Vit.

amin. Horm. 84, 415-448.

Sharma, J. L., Mpmahanga, C. P., Spedding, M., Germain, P., Stael, B.,

Dacquet, I., Laudef, V. and Harma, A. J. (2011) UPHAR-DB: new receptors and tools for easy searching and visualization of pharmaco-

dynamical data. Nucleic Acids Res. 39, D534-536.

Shukla, A. K., Xiao, K. and Lekfowiz, R. J. (2011) Emerging paradigms of 

beta-arrestin-dependent seven transmembrane receptor signal-

ing. Trends Biochem. Sci. 36, 457-469.

Soga, T., Ohishi, T., Matsi, T., Saio, T., Matsumota, M., Takasaka, J., 

Matsumoto, S., Kamohara, M., Hiyama, H., Yoshida, S., Momose, K.,

Ueda, Y., Matushime, H., Koby, M. and Furukichi, K. (2005) Lysophosphatidylcholine enhances glucose-dependent insulin se-

cretion via an orphan G-protein-coupled receptor. Biochem. Bio-

phys. Res. Commun. 328, 741-751.

Southern, C., Cook, J. M., Neetoo-Isseljee, Z., Taylor, D. L., Kettle-

worth, J., Schoonjans, K., Bianco, A. C. and Auwerx, J. (2006) Bile acids 

and regulates morphine-induced antinociception. Br. J. Pharmacol.

138, 941-953.

Valverde, O., Celerier, E., Baranyi, M., Vanderhaeghen, P., Maldo-

nado, R., Sperl, J., Bassalt, V. and Ledent, C. (2009) GPR3 receptor, 

a novel actor in the emotional-like responses. PloS one 4, e4704.

Vassilatis, D. K., Hohmann, J. G., Zeng, H., Li, F., Ranchalis, J. E., 

Mortrud, M. T., Brown, A., Rodriguez, S. S., Weller, J. R., Wright, A. C., 

Bergmann, J. E. and Gaitanaris, G. A. (2003) The G protein-

coupled receptor repertoires of human and mouse. Proc. Nat.

Acad. Sci. U.S.A. 100, 4903-4908.

Vassileva, G., Golovko, A., Markowitz, L., Abbondanzo, S. J., Zeng, 

M., Yang, S., Hoof, L., Tetzi, G., Levitan, D., Murgolo, N. J., Ke-

ane, K., Davis, H. R., Jr., Hedrick, J. and Gustafsson, E. L. (2006) 

Targeted deletion of Gpbar1 protects mice from cholesterol gall-

stone formation. J. Biochem. 39, 423-430.

Venkataraman, C. and Kuo, F. (2005) The G-protein coupled receptor 

GPR84 regulates IL-4 production by T lymphocytes in response to 

CD3 cross-linking. ImmunoLett. 101, 1456-1467.

Wang, J., Simonaviçius, N., Wu, X., Swanninath, G., Reagan, J., Tian 

and Ling, L. (2008a) Kynurenic acid as a ligand for orphan G 

protein-coupled receptor GPR35. J. Biol. Chem. 283, 22021-22028.

Wang, J., Wu, X., Simonaviçius, N., Tian, H. and Ling, L. (2008b) 

Medium-chain fatty acids as ligands for orphan G protein-coupled 

receptor GPR84. J. Biol. Chem. 283, 34457-34464.

Wang, L., Radu, C. G., Yang, L. V., Bentolila, L. A., Riedinger, M. and 

Witte, O. N. (2005) Lysophosphatidylcholine-induced surface re-

distribution regulates signaling of the murine G protein-coupled 

receptor G2A. Mol. Biol. Cell 16, 2234-2247.

Watanabe, M., Houten, S. M., Mataki, C., Christofotipo, M. A., Kim, B. W., 

Sato, H., Messaddeq, N., Narany, J. W., Ezaki, O., Kodama, T., 

Schoonjans, K., Bianco, A. C. and Auwerx, J. (2006) Bile acids 

induce energy expenditure by promoting intracellular thyroid hor-

mone activation. Nature 439, 484-489.

Yamashita, A., Oka, S., Tanikawa, T., Hayashi, Y., Nemoto-Sasaki, S. 

and Sugira, T. (2013) The actions and metabolism of lysophos-

phatidylinositol, an endogenous agonist for GPR55. Prostaglan-

dins Other Lipid Mediat. [Epub ahead of print].

Yan, J. J., Jung, J. S., Lee, J. E., Lee, J., Huh, S. O., Kim, H. S., Jung, 

K. C., Cho, Y. N., Nam, J. S., Suh, H. W., Kim, Y. H. and Song, D. K. (2004) 

Therapeutic effects of lysophosphatidylcholine in experi-

mental sepsis. Nat. Med. 10, 161-167.

Yanagida, K., Kurikawa, Y., Shimizu, T. and Ishii, S. (2013) Current 

progress in non-Edg family LPA receptor research. Biochim. Bio-

phys. Acta 1831, 33-41.

Yan, C. R., Wei, Y. J., Chen, L., Zhang, Q. H., Ma, J. Y., Luo, 

Y. B., Wang, Y. P., Hou, Y., Schatten, H., Liu, Z. H. and Sun, Q. Y. 

(2012) The G protein coupled receptor 3 is involved in cAMP and 

cGMP signaling and maintenance of meiotic arrest in porcine oocytes. 

PloS one 7, e38807.

Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Nguyen, D. G., 

Caldwell, J. S. and Chen, Y. A. (2009) Lipid G protein-coupled 

receptor ligand identification using beta-arrestin Pathfinder assay.
Yoshida, M., Miyazato, M. and Kangawa, K. (2012) Orphan GPCRs and methods for identifying their ligands. Methods Enzymol. 514, 33-44.
Zhang, B. L., Li, Y., Ding, J. H., Dong, F. L., Hou, Y. J., Jiang, B. C., Shi, F. X. and Xu, Y. X. (2012) Sphingosine 1-phosphate acts as an activator for the porcine Gpr3 of constitutively active G protein-coupled receptors. Journal of Zhejiang University. J. Zhejiang Univ. Sci. B 13, 555-566.
Zhang, R. and Xie, X. (2012) Tools for GPCR drug discovery. Acta Pharmacol. Sin. 33, 372-384.
Zhao, P. and Abood, M. E. (2013) GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sci. 92, 453-457.
Zhu, T., Gobeil, F., Vazquez-Tello, A., Leduc, M., Rihakova, L., Bosсолasco, M., Bkaily, G., Peri, K., Varma, D. R., Orvoine, R. and Chemtob, S. (2006) Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE2, PAF, and LPA1 receptors. Can. J. Physiol. Pharmacol. 84, 377-391.